Page last updated: 2024-08-18

pyrroles and niacin

pyrroles has been researched along with niacin in 50 studies

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19901 (2.00)18.7374
1990's4 (8.00)18.2507
2000's29 (58.00)29.6817
2010's16 (32.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fukuda, K; Higo, N; Noda, K; Otagiri, M; Tsuji, M; Yano, T1
Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S1
Wehmeier, T; Ziajka, PE1
Hoogerbrugge, N1
Stewart, BH; Whitfield, LR; Wu, X1
Breuer, HW1
Black, DM; McCormick, LS; McKenney, JM; Schaefer, EJ; Watkins, ML1
Crook, MA; Reynolds, TM; Wierzbicki, AS1
Stein, EA1
Chan, E; Charles, MA; Pan, J; Van, JT; Wasty, T; Wu, X1
Harman, SM; Hecht, HS1
Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE1
FINGER, H; FRETZDORFF, AM; SCHNEIDER, F; SEYNSCHE, K; WEITZEL, G1
Bays, HE; McGovern, ME2
Benz, R; Suter, PM1
Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L1
Elisaf, MS; Milionis, HJ1
McKenney, JM2
Langmann, T; Schmitz, G1
Borges, JL1
Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX1
Baum, J; Chen, Y; Crockett, R; Eisenberg, S; Huang, L; Larsen, R; Martinelli, M; Ng, J; Reider, P; Wang, X; Zhi, B1
Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP1
Bays, HE; Jones, PH; Kashyap, ML; Knopp, RH; McGovern, ME; McKenney, JM; Ruoff, GE1
Alsheikh-Ali, AA; Karas, RH1
Hashemi, MJ; Hekmat, M; Kouhi, A; Mojtahedzadeh, S; Naderi, N; Nobahar, R; Rafeiyian, S1
Bray, F; Chu, B; Dodge, JT; Hatsukami, TS; Lee, CD; Moore, AB; Phan, BA; Polissar, NL; Yuan, C; Zhao, XQ1
Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A1
Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ1
Godwinkumar, S; Muralidharan, S; Nagarajan, M; Nirmal, J; Peddanna, C; Saisivam, S1
Alrasadi, K; Alwaili, K; Awan, Z; Genest, J; Hafiane, A; Krimbou, L; Ruel, I1
Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q1
Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP1
Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP1
Schaefer, JR1
Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L1
Bandgar, TR; Faruqui, AA1
Jiang, P; Padley, RJ; Thakker, KM; Toth, PP1
Gajula, R; Inamadugu, JK; Mullangi, R; Pilli, NR; Ponneri, V; Ravi, VB1
Yeboah, J1
Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A1
Kapoor, A; Kumar, S; Rai, H; Sinha, N; Tewari, S1
Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A1
Abdel Hakiem, AF; Ali, HR; El-Kommos, ME; Mohamed, NA1
Jacob, RF; Mason, RP1
Dawani, ML; Mahboob, T; Yasmeen, G1

Reviews

10 review(s) available for pyrroles and niacin

ArticleYear
Peripheral neuropathy and lipid-lowering therapy.
    Southern medical journal, 1998, Volume: 91, Issue:7

    Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin

1998
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Current medical research and opinion, 2001, Volume: 17, Issue:1

    Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides

2001
Managing dyslipidemia in the high-risk patient.
    The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States

2002
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
    Praxis, 2004, Nov-10, Volume: 93, Issue:46

    Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization

2004
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A

    Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2005
High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy.
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:9

    Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cardiovascular Diseases; DNA-Binding Proteins; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Intestinal Mucosa; Kidney; Lipid Metabolism; Lipoproteins, HDL; Liver X Receptors; Macrophages; Niacin; Orphan Nuclear Receptors; Pyrroles; Receptors, Cytoplasmic and Nuclear

2005
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
    Vascular health and risk management, 2007, Volume: 3, Issue:4

    Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2007
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Current diabetes reviews, 2005, Volume: 1, Issue:2

    Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States

2005
[HDL level or HDL function as the primary target in preventive cardiology].
    Herz, 2012, Volume: 37, Issue:1

    Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation

2012
Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    Postgraduate medicine, 2012, Volume: 124, Issue:1

    Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Flushing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Niacin; Pyrroles

2012

Trials

17 trial(s) available for pyrroles and niacin

ArticleYear
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    The American journal of medicine, 1998, Volume: 104, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides; United States

1998
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
    Journal of internal medicine, 1998, Volume: 244, Issue:2

    Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides

1998
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    The American journal of cardiology, 2001, Aug-01, Volume: 88, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pyrroles

2001
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    The American journal of cardiology, 2003, Mar-15, Volume: 91, Issue:6

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors

2003
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Clinical therapeutics, 2006, Volume: 28, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome

2006
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Zhonghua yi xue za zhi, 2006, Sep-12, Volume: 86, Issue:34

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Female; Headache; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides

2006
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
    Atherosclerosis, 2007, Volume: 192, Issue:2

    Topics: Adult; Atorvastatin; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Niacin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome

2007
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study.
    American heart journal, 2007, Volume: 154, Issue:2

    Topics: Allylamine; Atherosclerosis; Atorvastatin; Carotid Stenosis; Colesevelam Hydrochloride; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Prospective Studies; Pyrroles

2007
Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Chinese medical journal, 2009, Jul-20, Volume: 122, Issue:14

    Topics: Aged; Anticholesteremic Agents; Apolipoproteins A; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Niacin; Pyrroles

2009
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
    Vascular health and risk management, 2010, Nov-24, Volume: 6

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States

2010
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
    Kardiologiia, 2011, Volume: 51, Issue:5

    Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Niacin; Plasminogen Activator Inhibitor 1; Pyrroles; Treatment Outcome; Tunica Intima

2011
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
    International journal of cardiology, 2013, Jul-15, Volume: 167, Issue:1

    Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome

2013
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
    Vascular health and risk management, 2012, Volume: 8

    Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States

2012
Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Atherosclerosis, 2013, Volume: 226, Issue:2

    Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrroles

2013
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians.
    The Indian journal of medical research, 2013, Volume: 138, Issue:6

    Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; India; Lipids; Male; Middle Aged; Niacin; Pyrroles; Risk Factors

2013
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Cardiovascular therapeutics, 2014, Volume: 32, Issue:4

    Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid

2014
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease.
    Iranian journal of kidney diseases, 2015, Volume: 9, Issue:1

    Topics: Adult; Atorvastatin; Biomarkers; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney Diseases; Male; Middle Aged; Niacin; Nitrates; Pakistan; Pyrroles; Recovery of Function; Renal Artery; Time Factors; Treatment Outcome; Ultrasonography, Doppler

2015

Other Studies

23 other study(ies) available for pyrroles and niacin

ArticleYear
Further evaluation of a new penetration enhancer, HPE-101.
    The Journal of pharmacy and pharmacology, 1993, Volume: 45, Issue:9

    Topics: Administration, Cutaneous; Animals; Drug Carriers; Estradiol; Female; Fluorouracil; Glycols; Indomethacin; Male; Mice; Mice, Hairless; Niacin; Pyrroles; Rats; Rats, Wistar; Skin Absorption; Triamcinolone Acetonide

1993
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
    Pharmaceutical research, 2000, Volume: 17, Issue:2

    Topics: Acetic Acid; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoic Acid; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carboxylic Acids; Carrier Proteins; Cell Polarity; Cyclosporine; Drug Interactions; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indicators and Reagents; Ionophores; Niacin; Protons; Pyrroles; Verapamil; Vinblastine

2000
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Dietary Fiber; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lactones; Male; Middle Aged; Niacin; Orlistat; Pyrroles; Statistics, Nonparametric; Treatment Outcome

2002
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
    The American journal of cardiology, 2002, Jun-01, Volume: 89, Issue:11

    Topics: Atorvastatin; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrroles; Retrospective Studies; Triglycerides

2002
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
    The American journal of cardiology, 2003, Jan-01, Volume: 91, Issue:1

    Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome

2003
[ADDITIONAL CLASSES OF COMPOUNDS INHIBITING TUMORS. I. CYTOSTATIC EFFECTS OF N- AND S-HYDROXYMETHYL COMPOUNDS].
    Hoppe-Seyler's Zeitschrift fur physiologische Chemie, 1963, Volume: 334

    Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Carbohydrate Metabolism; Carcinoma, Ehrlich Tumor; Cytostatic Agents; Formaldehyde; Hydantoins; Imidazoles; Isonicotinic Acids; Mice; Morpholines; Neoplasms, Experimental; Niacin; Niacinamide; Piperazines; Piperidines; Pyrroles; Research; Urea

1963
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Preventive cardiology, 2003,Fall, Volume: 6, Issue:4

    Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin

2003
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Drug safety, 2005, Volume: 28, Issue:3

    Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors

2005
Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.).
    American heart journal, 2005, Volume: 150, Issue:1

    Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Pyrroles; Simvastatin

2005
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
    Preventive cardiology, 2005,Fall, Volume: 8, Issue:4

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome

2005
[Drug combinations: statins and niacin].
    Arquivos brasileiros de cardiologia, 2005, Volume: 85 Suppl 5

    Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin

2005
A practical synthesis of 2-((1H-pyrrolo[2,3-b]pyridine-4-yl)methylamino)-5- fluoronicotinic acid.
    The Journal of organic chemistry, 2006, May-12, Volume: 71, Issue:10

    Topics: Molecular Structure; Niacin; Pyridines; Pyrroles

2006
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    The American journal of cardiology, 2007, Feb-01, Volume: 99, Issue:3

    Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration

2007
Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2007, Volume: 16, Issue:4

    Topics: Adolescent; Aortic Stenosis, Supravalvular; Aortic Valve Stenosis; Atorvastatin; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Niacin; Pyrroles

2007
Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation.
    Chemical & pharmaceutical bulletin, 2008, Volume: 56, Issue:10

    Topics: Atorvastatin; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Incompatibility; Drug Stability; Drug Storage; Excipients; Hardness; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypromellose Derivatives; Methylcellulose; Niacin; Pyrroles; Solubility; Tablets

2008
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    The American journal of cardiology, 2008, Nov-15, Volume: 102, Issue:10

    Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Deficiency Diseases; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pilot Projects; Pyrroles; Severity of Illness Index

2008
Last fall I began taking daily doses of 1,500 mg of niacin, in addition to the 40 mg of Lipitor I've been taking for several years. Within six months, my LDL and triglycerides were down significantly and my HDL was higher. If my next bi-annual blood test
    Heart advisor, 2008, Volume: 11, Issue:9

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrroles; Triglycerides

2008
Managing dyslipidaemia: evolving role of combination therapy.
    Journal of the Indian Medical Association, 2011, Volume: 109, Issue:8

    Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles

2011
Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
    Biomedical chromatography : BMC, 2012, Volume: 26, Issue:11

    Topics: Atorvastatin; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Humans; Linear Models; Liquid-Liquid Extraction; Male; Nevirapine; Niacin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2012
Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
    Atherosclerosis, 2013, Volume: 226, Issue:2

    Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles

2013
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones

2014
Micellar electrokinetic chromatographic determination of rosuvastatin in rabbit plasma and evaluation of its pharmacokinetics and interaction with niacin.
    Biomedical chromatography : BMC, 2014, Volume: 28, Issue:12

    Topics: Animals; Atorvastatin; Chromatography, Micellar Electrokinetic Capillary; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Hydrogen-Ion Concentration; Limit of Detection; Linear Models; Male; Niacin; Pyrimidines; Pyrroles; Rabbits; Reproducibility of Results; Rosuvastatin Calcium; Sodium Dodecyl Sulfate; Sulfonamides

2014
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
    Biochimica et biophysica acta, 2015, Volume: 1848, Issue:2

    Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles

2015